Techniques like lipid conjugation, nanoparticle formulations, prodrug design, and receptor-mediated transcytosis could be explored to modify tofersen’s properties and augment its ability to penetrate the BBB, thus amplifying therapeutic efficacy in conditions like SOD1-related ALS [159]. Here, SOD1 is linked to amyotrophic lateral sclerosis.